Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma. | 2023 | NICE |
Clinical, pharmacoeconomic, and stakeholder input combined report: Pembrolizumab (Keytruda). | 2023 | CADTH |
Comparative efficacy and safety of immune checkpoint inhibitors for unresectable advanced melanoma: A systematic review and network meta-analysis. | 2023 | International Immunopharmacology |
A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases. | 2023 | EBioMedicine |
The role of immune checkpoint inhibitors (ICI) as adjuvant treatment in renal cell carcinoma (RCC): A systematic review and meta-analysis. | 2023 | Clinical Genitourinary Cancer |
Efficacy and safety of treatments for advanced thymic carcinoma after failure of first-line platinum-based chemotherapy: A systematic literature review and meta-analysis. | 2023 | Lung Cancer |
Anti-TIGIT therapies for solid tumors: a systematic review. | 2023 | ESMO |
Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis. | 2023 | Lung Cancer |
Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma. | 2022 | NICE |
Clinical benefit of first-line programmed death-1 antibody plus chemotherapy in low programmed cell death ligand 1–expressing esophageal squamous cell carcinoma: a post hoc analysis of jupiter-06 and meta-analysis. | 2022 | Journal of Clinical Oncology |
Efficacy and safety of neoadjuvant chemoimmunotherapy in resectable esophageal squamous cell carcinoma: a meta-analysis. | 2022 | Annals of Surgical Oncology |
Treatment of metastatic colorectal cancer: ASCO guideline. | 2022 | Journal of Clinical Oncology |
Efficacy and safety of pembrolizumab based therapies in triple-negative breast cancer: a systematic review of clinical trials | 2021 | Critical Reviews in Oncology / Hematology |
Comparative efficacy and safety of PD-1/PD-L1 inhibitors for patients with solid tumors: a systematic review and Bayesian network meta-analysis. | 2021 | Journal of Cancer |
Pembrolizumab with axitinib for untreated advanced renal cell carcinoma. | 2020 | NICE |
Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma. | 2020 | NICE |
First-line treatment of metastatic renal cell carcinoma in the immuno-oncology era: systematic review and network meta-analysis. | 2020 | Clinical Genitourinary Cancer |
Immune checkpoint inhibitors in advanced or metastatic mucosal melanoma: a systematic review. | 2020 | Therapeutic Advances in Medical Oncology |
Systemic therapy for metastatic renal cell carcinoma in the first‑line setting: a systematic review and network meta‑analysis. | 2020 | Cancer Immunology, Immunotherapy |
Nivolumab plus ipilimumab versus existing immunotherapies in patients with PD-L1-positive advanced non-small cell lung cancer: a systematic review and network meta-analysis. | 2020 | Cancers |
Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer. | 2020 | Cochrane Database of Systematic Reviews |
Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: a systematic review. | 2020 | PLoS One |
What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis. | 2020 | BMJ Open |
Efficacy and safety of immune checkpoint inhibitors in patients with advanced non–small cell lung cancer (NSCLC): a systematic literature review. | 2020 | OncoImmunology |
Targeted therapy for metastatic renal cell carcinoma. | 2020 | Cochrane Database of Systematic Reviews |
Comparative efficacy of first-line immune-based combination therapies in metastatic renal cell carcinoma: a systematic review and network meta-analysis. | 2020 | Cancers |
Economic evaluation of systemic treatments for advanced melanoma: a systematic review. | 2020 | Value in Health |
Immune checkpoint inhibitors and immune-related adverse events in patients with advanced melanoma: a systematic review and network meta-analysis. | 2020 | JAMA Network |
Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis. | 2020 | European Journal of Clinical Pharmacology |
Immune checkpoint inhibitors in advanced acral melanoma: a systematic review. | 2020 | Frontiers in Oncology |
Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for treatment of recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and network meta-analysis. | 2020 | Therapeutic Advances in Medical Oncology |
First-line treatments for advanced renal-cell carcinoma with immune checkpoint inhibitors: systematic review, network meta-analysis and cost-effectiveness analysis. | 2020 | Therapeutic Advances in Medical Oncology |
A systematic review and meta-analysis of immune-related adverse events of anti-PD-1 drugs in randomized controlled trials. | 2020 | Technology in Cancer Research & Treatment |
Systematic review and network meta-analysis of immune checkpoint inhibitors in combination with chemotherapy as a first-line therapy for extensive-stage small cell carcinoma. | 2020 | Cancers |
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis. | 2019 | Lung Cancer |
Treatment-related adverse events of PD-1 and PD-L1 Inhibitors in clinical trials: a systematic review and meta-analysis. | 2019 | JAMA Oncology |
Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis. | 2019 | Immunotherapy |
The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: a systematic review and meta‐analysis. | 2019 | Journal of Cellular Physiology |
A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma. | 2019 | European Journal of Cancer |
Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: a Bayesian network meta-analysis. | 2019 | Critical Reviews in Oncology / Hematology |
First-line pembrolizumab versus pembrolizumab plus chemotherapy versus chemotherapy alone in non-small-cell lung cancer: a systematic review and network meta-analysis. | 2019 | Clinical Lung Cancer |
Risk of pneumonitis and pneumonia associated with immune checkpoint inhibitors for solid tumors: a systematic review and meta-analysis. | 2019 | Frontiers in Immunology |
Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: a Bayesian network analysis. | 2019 | EBioMedicine |
Comparative efficacy of second- and subsequent-line treatments for metastatic NSCLC: a fractional polynomials network meta-analysis of cancer immunotherapies. | 2019 | Clinical Lung Cancer |
First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy. | 2019 | Journal for ImmunoTherapy of Cancer |
First-line immune checkpoint inhibitors for advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK): a systematic review and network meta-analysis. | 2019 | Journal of Thoracic Disease |
The differences in the safety and tolerability of immune checkpoint inhibitors as treatment for non-small cell lung cancer and melanoma: network meta-analysis and systematic review. | 2019 | Frontiers in Pharmacology |
Chemotherapy in combination with immune checkpoint inhibitors for the first-line treatment of patients with advanced non-small cell lung cancer: a systematic review and literature-based meta-analysis. | 2019 | Frontiers in Oncology |
Comparison of immune checkpoint inhibitors between older and younger patients with advanced or metastatic lung cancer: a systematic review and meta-analysis. | 2019 | BioMed Research International |
The risk of immune-related endocrine disorders associated with anti-PD-1 inhibitors therapy for solid tumors: a systematic review and meta-analysis. | 2018 | International Immunopharmacology |
A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. | 2018 | Journal for ImmunoTherapy of Cancer |
Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. | 2018 | BMJ |
Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. | 2018 | BMJ |
Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. | 2018 | Cochrane Database of Systematic Reviews |
Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials. | 2018 | Medicine |
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: an indirect comparison between nivolumab, pembrolizumab and atezolizumab. | 2018 | International Journal of Cancer |